In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guided Therapeutics bullish on cervical scan despite second FDA knock-back

This article was originally published in Clinica

Executive Summary

Guided Therapeutics’ share price has plunged again after it was hit by a second FDA rejection of its flagship LuViva noninvasive cervical cancer scanning technology. Although a blow to the company, the agency’s not-approvable letter is potentially good news for the producers of rival cervical cancer screening techniques such as Pap smears and human papillomavirus (HPV) testing, including Hologic and Qiagen.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts